The benefits of physician-pharmacist collaboration

This collaborative care model can improve the management of patients with chronic diseases like hypertension and diabetes. But implementation has its challenges.

Over the past decade, physician-pharmacist collaborative practices have gained traction in primary care as a way to implement team-based-care models. And there is evidence pointing to the effectiveness of this multi-disciplinary health care team approach, in which pharmacists are typically responsible for such things as obtaining medication histories, identifying barriers to adherence, and adjusting medication regimens.

Several studies have shown the significant impact that physician-pharmacist collaborative management (PPCM) can have on blood pressure (BP) control among patients with hypertension (HTN).1-8 Additionally, PPCM may have positive effects on Hba1c reduction and diabetes control,9-11 suggesting that benefits may extend to other chronic diseases, too.

In the review that follows, we’ll detail the impact that PPCM can have on patient care, health-care utilization, and cost effectiveness. (For a look at PPCM “in action,” see the sidebar on page E2.) We’ll also review the challenges of implementing this model that, at present, is mostly found in academically-affiliated clinics and large health systems.

PPCM impacts chronic diseases

The current literature is rife with studies investigating the impact of PPCM on chronic diseases in the primary care setting.1-12 Although no specific guidelines on implementing PPCM exist, these studies utilized similar interventions that provided pharmacists with the ability to manage medication therapy under the supervision of a physician. A number of these studies incorporated collaborative practice plans to delineate the specific duties performed by physicians and pharmacists.2,6,8,10,11 Responsibilities for pharmacists often included assessing vital signs, reviewing laboratory parameters and ordering appropriate tests, providing patient education, screening for drug interactions, identifying barriers to medication adherence, and adjusting...
The physician-pharmacist collaborative care model in action

For patients with chronic diseases such as hypertension and diabetes, pharmacists can be invaluable members of multidisciplinary health care teams by providing direct consultation to optimize pharmacotherapy. Although their particular role and responsibilities can vary widely from one primary care setting to the next, the following describes the general workflow of a physician-pharmacist collaborative care model in action.

The patient, 60-year-old Isabel B, arrives for an appointment for pharmacotherapy management of her hypertension. After checking in, a registered nurse (RN), medical assistant (MA), or the pharmacist obtains her vital signs, height, and weight prior to rooming. Additionally, any necessary point-of-care lab tests are obtained at this time.

Once the patient is roomed, the pharmacist collects a thorough medication history from Ms. B, verifying and updating her current medication list, confirming the dose and frequency of each medication, and gathering information regarding adverse effects and barriers to adherence. The pharmacist may also review current laboratory results and vital signs to assess the appropriateness and therapeutic efficacy of the current drug therapy regimen.

Depending upon the collaborative practice plan in place, one of the following steps may occur:

A. The pharmacist makes a change to Ms. B’s medication regimen and orders any necessary laboratory tests for monitoring. A progress note is forwarded to Ms. B’s primary care provider (PCP) to inform him/her of the changes made to the regimen and the follow-up interval.

B. The pharmacist presents pharmacotherapy recommendations to the attending physician or Ms. B’s PCP. The therapeutic and monitoring plans are discussed and approved as a team at the time of Ms. B’s visit.

C. The pharmacist sends a message to Ms. B’s PCP regarding information discovered during the interview and provides recommendations for a treatment plan based on the visit. The PCP reviews the recommendations, and can either 1) send approval to the pharmacist through a message or 2) implement the appropriate drug therapy changes at Ms. B’s next visit.

In Cases A and B, the pharmacist then reviews the final pharmacotherapy plan with Ms. B, discusses the medication and monitoring parameters, answers any questions related to the new treatment regimen, and schedules a follow-up visit. In Case C, the pharmacist may still provide medication counseling and answer questions related to drug therapy during the visit; however, review of the final pharmacotherapy plan may be done over the telephone after approval by the PCP. Alternatively, a follow-up appointment with Ms. B’s PCP can be scheduled shortly after the visit with the pharmacist to discuss any recommended drug therapy changes.

PPCM leads to greater BP reductions, improved BP control

The majority of research surrounding PPCM has focused on uncontrolled HTN.1-8 Patients in many of these studies saw a pharmacist in a specialized HTN clinic, where the multidisciplinary staff performed a thorough evaluation of the patient’s current hypertensive management. The pharmacists in these PPCM programs closely monitored patients and made adjustments to antihypertensive regimens as necessary. Systolic and diastolic BP reductions in the intervention groups ranged from 14 to 36 mm Hg and 7 to 15 mm Hg, respectively.1-5,7,8 The percentage of patients with BP control at the end of the studies ranged from 43% to 89%.1,3,4,6,7

In a prospective, cluster-randomized trial performed at 32 primary care offices in 15 states, researchers assigned 625 patients with uncontrolled HTN to receive physician-pharmacist collaborative care or usual care with primary care provider management.7 As part of the PPCM intervention, clinical pharmacists conducted a thorough medical record review and a structured interview of the patients. During the interview, the clinical pharmacists reviewed the patient’s medication history, assessed the patient’s knowledge of BP medications, and addressed any barriers to adherence. In collaboration with the physician, the pharmacists developed a care plan with recommendations for optimizing the drug regimen. After the baseline visit, the pharmacists conducted structured face-to-face interviews with patients at 1, 2, 4, 6, and 8 months, with additional visits scheduled if BP was still uncontrolled.

At 9 months, patients in the PPCM group had significantly greater reductions in BP than those in the control group, and BP control was achieved in 43% of the PPCM group vs 34% of the control group. This study corroborates results from previous (similar) studies investigating the impact of PPCM on patients with uncontrolled HTN.1-6

PPCM helps patients reduce their HbA1c levels

Researchers have also studied the impact of medication regimens. The table1-12 provides a summary of studies investigating the impact of PPCM in the primary care setting.

---

1. In a prospective, cluster-randomized trial performed at 32 primary care offices in 15 states, researchers assigned 625 patients with uncontrolled HTN to receive physician-pharmacist collaborative care or usual care with primary care provider management. As part of the PPCM intervention, clinical pharmacists conducted a thorough medical record review and a structured interview of the patients. During the interview, the clinical pharmacists reviewed the patient’s medication history, assessed the patient’s knowledge of BP medications, and addressed any barriers to adherence. In collaboration with the physician, the pharmacists developed a care plan with recommendations for optimizing the drug regimen. After the baseline visit, the pharmacists conducted structured face-to-face interviews with patients at 1, 2, 4, 6, and 8 months, with additional visits scheduled if BP was still uncontrolled.

At 9 months, patients in the PPCM group had significantly greater reductions in BP than those in the control group, and BP control was achieved in 43% of the PPCM group vs 34% of the control group. This study corroborates results from previous (similar) studies investigating the impact of PPCM on patients with uncontrolled HTN.

1. In a prospective, cluster-randomized trial performed at 32 primary care offices in 15 states, researchers assigned 625 patients with uncontrolled HTN to receive physician-pharmacist collaborative care or usual care with primary care provider management. As part of the PPCM intervention, clinical pharmacists conducted a thorough medical record review and a structured interview of the patients. During the interview, the clinical pharmacists reviewed the patient’s medication history, assessed the patient’s knowledge of BP medications, and addressed any barriers to adherence. In collaboration with the physician, the pharmacists developed a care plan with recommendations for optimizing the drug regimen. After the baseline visit, the pharmacists conducted structured face-to-face interviews with patients at 1, 2, 4, 6, and 8 months, with additional visits scheduled if BP was still uncontrolled.

At 9 months, patients in the PPCM group had significantly greater reductions in BP than those in the control group, and BP control was achieved in 43% of the PPCM group vs 34% of the control group. This study corroborates results from previous (similar) studies investigating the impact of PPCM on patients with uncontrolled HTN.

---

1. In a prospective, cluster-randomized trial performed at 32 primary care offices in 15 states, researchers assigned 625 patients with uncontrolled HTN to receive physician-pharmacist collaborative care or usual care with primary care provider management. As part of the PPCM intervention, clinical pharmacists conducted a thorough medical record review and a structured interview of the patients. During the interview, the clinical pharmacists reviewed the patient’s medication history, assessed the patient’s knowledge of BP medications, and addressed any barriers to adherence. In collaboration with the physician, the pharmacists developed a care plan with recommendations for optimizing the drug regimen. After the baseline visit, the pharmacists conducted structured face-to-face interviews with patients at 1, 2, 4, 6, and 8 months, with additional visits scheduled if BP was still uncontrolled.

At 9 months, patients in the PPCM group had significantly greater reductions in BP than those in the control group, and BP control was achieved in 43% of the PPCM group vs 34% of the control group. This study corroborates results from previous (similar) studies investigating the impact of PPCM on patients with uncontrolled HTN.

---

1. In a prospective, cluster-randomized trial performed at 32 primary care offices in 15 states, researchers assigned 625 patients with uncontrolled HTN to receive physician-pharmacist collaborative care or usual care with primary care provider management. As part of the PPCM intervention, clinical pharmacists conducted a thorough medical record review and a structured interview of the patients. During the interview, the clinical pharmacists reviewed the patient’s medication history, assessed the patient’s knowledge of BP medications, and addressed any barriers to adherence. In collaboration with the physician, the pharmacists developed a care plan with recommendations for optimizing the drug regimen. After the baseline visit, the pharmacists conducted structured face-to-face interviews with patients at 1, 2, 4, 6, and 8 months, with additional visits scheduled if BP was still uncontrolled.

At 9 months, patients in the PPCM group had significantly greater reductions in BP than those in the control group, and BP control was achieved in 43% of the PPCM group vs 34% of the control group. This study corroborates results from previous (similar) studies investigating the impact of PPCM on patients with uncontrolled HTN.
TABLE

Physician-pharmacist collaborative management: What the literature tells us

<table>
<thead>
<tr>
<th>Study</th>
<th>Methods</th>
<th>Intervention</th>
<th>Outcomes</th>
<th>Results</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Borenstein JE, et al. 2003</td>
<td>Randomized, comparative trial of 197 patients with uncontrolled HTN</td>
<td>HTN clinic run by pharmacists who: •Measured BP •Assessed drug adherence •Evaluated adverse effects •Provided education •Made treatment recommendations with physician approval Follow-up visits every 2-4 weeks</td>
<td>Primary: difference in BP changes between PPCM and UC groups Secondary: differences in proportion of patients achieving goal BP</td>
<td>Primary (PPCM vs UC) •SBP: 22 mm Hg vs 11 mm Hg (P&lt;.01) •DBP: 7 mm Hg vs 8 mm Hg (P=.53) Secondary (PPCM vs UC) •60% vs 43% achieved BP goal (P=.02)</td>
<td>Patients with uncontrolled HTN who received PPCM care had greater reductions in systolic BP and were more likely to achieve goal BP.</td>
</tr>
<tr>
<td>Kiel PJ, et al. 2005</td>
<td>Retrospective chart review of 157 patients enrolled in a pharmacist-coordinated diabetes management program</td>
<td>Program provided: •Patient education •Medication adjustments •Lab test monitoring Patients were referred to the program if they had a history of poor glycemic control or a new diagnosis of T2DM</td>
<td>Comparison between pre- and post-PPCM •Proportion of patients at goal A1C (&lt;7%) •Mean A1C reduction •Proportion of patients with LDL-C &lt;100 mg/dL •Frequency of microalbumin screening</td>
<td>Pre- vs post-PPCM •At goal A1C: 19% vs 50% (P&lt;.001) •Mean A1C reduced by 1.6% (P&lt;.001) •At goal LDL-C: 30% vs 56% (P&lt;.001) •Microalbumin screening: 51% vs 78% (P&lt;.001)</td>
<td>Researchers observed significant clinical improvement in patients with diabetes enrolled in a clinical pharmacist-coordinated management program.</td>
</tr>
<tr>
<td>Hunt JS, et al. 2008</td>
<td>Prospective, single-blind RCT of 463 patients with uncontrolled HTN</td>
<td>Primary care clinic visits where pharmacists: •Reviewed medications and lifestyle •Assessed vital signs •Screened for adverse drug reactions •Identified adherence barriers •Provided education •Optimized antihypertensive regimen</td>
<td>Primary: •Mean BP difference between PPCM and UC groups •Proportion attaining goal BP (&lt;140/90 mm Hg) Secondary: •Health care utilization •Quality of life and satisfaction</td>
<td>Primary (PPCM vs UC) •137/75 mm Hg vs 143/78 mm Hg (P=.007 for SBP; P=.003 for DBP) •62% vs 44% attained goal (P=.003) Secondary •Higher total clinic visits in PPCM group •No significant difference in quality of life or satisfaction</td>
<td>Incorporation of pharmacists into the management of HTN significantly improved BP control.</td>
</tr>
</tbody>
</table>

PPCM strategies on the management of diabetes mellitus. In one retrospective study of 157 patients, implementation of a pharmacy-coordinated diabetes (any type) management program significantly improved HbA1c and increased the percentage of patients reaching their HbA1c goal. Furthermore, researchers observed improvements in low-density lipoprotein cholesterol (LDL-C) levels and an increased number of patients obtaining a microalbumin screening after initiation of the program.

A more recent prospective, multicenter cohort study of 206 patients with uncontrolled type 2 diabetes had similar results. In collaboration with the primary care physician...
<table>
<thead>
<tr>
<th>Study</th>
<th>Methods</th>
<th>Intervention</th>
<th>Outcomes</th>
<th>Results</th>
<th>Conclusions</th>
</tr>
</thead>
</table>
| Carter BL, et al. 2008 | Prospective, cluster RCT of 179 patients ages 21-85 years with uncontrolled HTN | Clinic visit with pharmacist who:  
  • Assessed current regimen  
  • Suggested ways to improve BP control  
  • Recommended adherence aids  
  • Educated patients  
  Follow-up visits at 2, 4, 6, and 8 mos | Comparison between PPCM and UC groups:  
  • Mean BP at 9 mos  
  • 24-hour BP at 9 mos  
  • BP control | PPCM vs UC  
  • Mean BP: 124/75 mm Hg vs 133/79 mm Hg (P<.001)  
  • 24-hour BP: 121/69 mm Hg vs 131/74 mm Hg (P<.001)  
  • BP control: 89.1% vs 52.9% (P<.001) | The PPCM intervention was associated with significant reductions in BP and improvements in BP control. |
| Carter BL, et al. 2009 | Prospective, cluster RCT of 402 patients with uncontrolled HTN taking ≤3 antihypertensive medications | • Implementation of collaboration was left to the discretion of each clinic  
  • Recommendations made were based on JNC-7 guidelines  
  • Pharmacists assessed medications/BP at baseline, 1 month, and by telephone at 3 mos (and more frequently if needed)  
  • Pharmacist recommendations were provided face-to-face with physicians present | Comparison between PPCM and UC groups:  
  • BP control  
  • Mean BP reduction | PPCM vs UC  
  • BP control: 63.9% vs 29.9% (P<.001)  
  • Mean BP reduction: 21/10 mm Hg vs 7/5 mm Hg (P<.05) | An intervention consisting of physician and pharmacist collaboration significantly improved BP control compared with usual care. |
| Weber CA, et al. 2010  | Prospective, cluster RCT of 179 patients ages 21-85 years with uncontrolled HTN | A pharmacist interviewed and evaluated patients to determine:  
  • Patient factors impeding achieving goal BP  
  • The patient’s current treatment regimen vs clinical guidelines  
  Pharmacists discussed treatment recommendations with PCP  
  At baseline and at 9 mos, patients performed ambulatory BP monitoring | Comparison of change in 24-hour mean ambulatory SBP and DBP from baseline to 9 mos | PPCM vs UC  
  • SBP: -14.1 mm Hg vs -5.5 mm Hg (P<.001)  
  • DBP: -6.8 mm Hg vs -2.8 mm Hg (P<.001) | The PPCM group achieved significantly greater reductions in BP than did the UC group. |
| Farland MZ, et al. 2013 | Prospective, multicenter, cohort study of 206 patients with T2DM and uncontrolled A1C, BP, or LDL-C |  
  • Pharmacists educated patients, reviewed blood glucose logs, ordered and monitored labs, and adjusted medications  
  • Follow-up visits occurred at 1- to 12-wk intervals | Pre- vs post-PPCM  
  • Reduction in A1C  
  • Percentage of patients achieving goal A1C (<7%) | Pre- vs post-PPCM  
  • Mean A1C: 8.9% vs 7.7% (P<.0001)  
  • Patients at goal A1C: 12.8% vs 36.8% (P=.0002) | PPCM has a positive impact on glycemic control and diabetes-related health maintenance. |
<table>
<thead>
<tr>
<th>Study</th>
<th>Methods</th>
<th>Intervention</th>
<th>Outcomes</th>
<th>Results</th>
<th>Conclusions</th>
</tr>
</thead>
</table>
| Howard-Thompson A, et al.11 2013         | Prospective, multicenter, cohort trial of 206 patients with T2DM and uncontrolled A1C, BP, or LDL-C | • Pharmacists educated patients, reviewed blood glucose logs, ordered and monitored labs, and adjusted medications  
• Follow-up visits occurred at 1- to 12-wk intervals | Pre- vs post-PPCM  
• Reduction in SBP, DBP, and LDL-C  
• Percentage of patients achieving BP goal (<130/80 mm Hg)  
• Percentage of patients achieving LDL-C goal (<100 mg/dL) | Pre- vs post-PPCM  
• SBP: 132.2 mm Hg vs 127 mm Hg (P<.0001)  
• DBP: 77.2 mm Hg vs 74.3 mm Hg (P<.0001)  
• At BP goal: 32% vs 53.9% (P<.0001)  
• LDL-C: 100.5 mg/dL vs 89.1 mg/dL (P<.0001)  
• At goal LDL-C: 57.6% vs 69.4% (P=.023) | PPCM has a positive impact on CV risk in patients with T2DM. |
| Gums TH, et al.12 2014                   | Prospective pre-post study of 126 patients ≥12 years of age with persistent asthma | Pharmacists:  
• Assessed asthma severity  
• Educated patients on proper drug administration  
• Provided asthma action plan  
Follow-up visits occurred after 1, 2, 4, 6, and 9 mos; optional visits at 3, 5, 7, and 8 mos for patients with poor asthma control | Combined number of asthma-related ED visits and hospitalizations  
ACT scores after implementing PPCM | Number of ED visits and/or hospitalizations decreased 30% during intervention (16.7% vs 12.7%; P=.052)  
ACT scores significantly improved after implementing PPCM (16.76 vs 19.02; P<.0001) | A PPCM care model reduced asthma-related ED visits and hospitalizations and improved asthma control and quality of life. |
| Hirsch JD, et al.6 2014                  | Randomized, pragmatic clinical trial of 166 patients with uncontrolled HTN | Pharmacists:  
• Assessed treatment goals  
• Reviewed and/or ordered labs  
• Adjusted antihypertensive regimens  
Follow-up visits at 3, 6, and 9 mos | Change in SBP at 6 months after initial visit  
Percentage of patients at BP goal (<140/90 mm Hg or ≤130/80 mm Hg with T2DM) | PPCM vs UC  
• Change in SBP: -7.1 mm Hg vs +1.6 mm Hg (P=.008)  
• Patients at BP goal: 70% vs 52% (P=.02) | In patients with HTN, PPCM was more effective at lowering BP than UC. |
| Carter BL, et al.7 2015                  | Prospective, cluster randomized trial of 625 patients with uncontrolled HTN | Pharmacists conducted a medical record review and structured interview to determine the patient's medication history, knowledge of BP medications, and barriers to adherence  
Follow-up telephone call at 2 wks; structured visits at 1, 2, 4, 6, and 8 mos | Proportion of patients at BP goal (<140/90 mm Hg or <130/80 mm Hg with T2DM or CKD) at 9 mos  
Reduction in mean SBP and DBP at 9 mos | PPCM vs UC  
BP control: 43% vs 34% (P=.059)  
SBP: 131.6 mm Hg vs 138.2 mm Hg (P=.002)  
DBP: 76.3 mm Hg vs 78 mm Hg (P=.005) | Although no significant difference was seen with BP control, mean BP was significantly reduced in the intervention group. |
TABLE
Physician-pharmacist collaborative management: What the literature tells us1-12 continued

<table>
<thead>
<tr>
<th>Study</th>
<th>Methods</th>
<th>Intervention</th>
<th>Outcomes</th>
<th>Results</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sisson EM, et al.8 2016</td>
<td>Quasi-experimental longitudinal pre-post cohort study of 172 uninsured patients referred to a free hypertension clinic</td>
<td>Collaborative practice agreement in which pharmacists: • Reconciled medication lists • Completed clinical interviews • Conducted physical exams • Developed treatment plans</td>
<td>Change in mean SBP and DBP from baseline Percentage of patients reaching BP goal (&lt;140/90 mm Hg)</td>
<td>Mean SBP/DBP reduced by 25/15 mm Hg (156/98 mm Hg to 131/83 mm Hg; P&lt;.0001) Patients reaching goal BP increased from baseline (17.4% to 68%; P&lt;.05)</td>
<td>PPCM improved hypertension control in an uninsured patient population.</td>
</tr>
</tbody>
</table>

ACT, asthma control test; BP, blood pressure; CV, cardiovascular; CKD, chronic kidney disease; DBP, diastolic blood pressure; ED, emergency department; HTN, hypertension; JNC-7, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; LDL-C, low-density lipoprotein cholesterol; PPCM, physician-pharmacist collaborative management; RCT, randomized controlled trial; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus; UC, usual care.

Benefits derive from altered health care utilization
Researchers attribute much of the benefit observed with PPCM to the increased—albeit different—health-care utilization among the patients in the intervention groups. In general, patients participating in PPCM have an increased total number of visits, but more of those visits are with pharmacists and fewer are with physicians; they also are prescribed more medications, but don’t necessarily take more pills per day.1,2,5 In the end, patients have been found to achieve significantly better disease control without compromising quality of life or satisfaction.2

Some studies have found that continued pharmacist involvement may be necessary to sustain the benefits achieved.6 However, other studies have suggested that the benefits are maintained even after discontinuation of the pharmacist intervention.14,15 Thus, further research is necessary to determine which patients may benefit most from ongoing involvement with a pharmacist.

How cost-effective is the PPCM model?
Implementing a PPCM model in a primary care setting often hinges upon whether the intervention will be cost-effective. Several
Researchers found that patients in a physician-pharmacist collaborative management model had significantly greater reductions in BP than those in the control group.

**Researchers**

Overcoming implementation challenges

Implementation of pharmacist collaboration within primary care medicine may pose a challenge, as the requirements and resources vary widely among primary care settings. Health-system administrators, for example, may need to reorganize the clinic structure and budget resources in order to overcome some of the obstacles to implementing a PPCM model.

Experts have reported several strategies that help in establishing PPCM within primary care clinics, including proactively identifying patients who may benefit from pharmacist intervention, requiring appropriate training and credentialing of pharmacists, and establishing a set schedule for pharmacists to interview patients. Clinics would also be well served to model interventions outlined in the studies mentioned in this article and provide adequate time for pharmacists to perform structured activities, including review of medication history, assessment of current disease state control, and adjustment of medication therapy regimens. And, of course, given the diversity of primary care settings, administrators will need to identify the specific PPCM strategies that best complement their respective collaborative practice plans and environments.

The lack of well-defined reimbursement models for pharmacy services has presented a challenge for generating revenue and effectively implementing PPCM within many primary care settings. Currently, the Centers for Medicare and Medicaid Services and third-party payers do not recognize pharmacists as independent providers, creating a barrier for obtaining reimbursement for clinical pharmacy services. Typically, pharmacists have charged for clinic visits under a consultant physician through the “incident to” billing model, with the option to bill at higher levels if the patient was seen jointly with the physician.

**Can this model benefit the underserved?**

A prospective, cluster-randomized clinic study has shown pharmacist intervention to reduce racial and socioeconomic disparities in the treatment of elevated BP. This study is the first to show that a team-care model can overcome inequalities arising from low income, low patient education status, and little or no insurance to produce the same health care benefit as in those with higher socioeconomic and educational status. This type of collaborative care model may be particularly beneficial when incorporated within a PCMH catering to underserved populations.

However, sparse data currently exist regarding the benefits of the PPCM model within a PCMH, despite the fact that integration of this type of collaborative model is expected to contribute positively to patient care.

**Physician acceptance of pharmacist involvement is mixed**

While physician acceptance of pharmacist recommendations is generally high, at least one study indicated that some health-care professionals in patient-care teams are reluctant to incorporate pharmacists into a PCMH. Reasons include difficulty in coordination of care with pharmacy services and limited knowledge by other professionals of pharmacists’ training.

**Centralization can combat a lack of resources**

As noted earlier, primary care offices that implement PPCM models are mostly academically affiliated or are part of large health systems. Many private primary care offices lack the resources to employ a pharmacist in their office. As an alternative, prospective clinical trials are looking at a central-
Implementation of a physician-pharmacist collaborative management model reduced the average HbA1c by 1.2%.

References